The performance of EarlyCDT-Lung meets all American Thoracic Society criteria for a biomarker test’s clinical readiness for use in indeterminate pulmonary nodules:6
- Improves on the accuracy of current diagnostic methods
- The accuracy is sufficient to move the pretest probability of malignancy beyond a clinical decision threshold
- The balance of benefits and harms strongly favours using the test
- Calculations can be performed on the relative benefit of a true-positive to false-positive to have clinical benefit. Oncimmune’s simple risk calculator and our clinician support material facilitate these calculations.